Theravance Biopharma Inc. TBPH
$16.55
▲ +0.91% 24H
About
Theravance Biopharma is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines targeting respiratory disease, inflammatory and immunology conditions, and rare disorders. The company's flagship product, YUPELRI (revefenacin), is an FDA-approved once-daily, nebulized …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees90
TickerTBPH
Statistics
Market Cap$852.3M
Revenue (TTM)$107.5M
Net Income$105.9M
Net Margin98.5%
EPS$2.06
P/E7.39
P/S7.74
P/B2.92
EV/EBITDA74.48
ROE50.2%
Dividend Yield—
Price$16.55
Data: Twelve Data · Revenue = mcap / P/S